Medtronic's stent for twisted arteries cleared:
This article was originally published in Clinica
Executive Summary
Medtronic has received clearance from the FDA to market a new stent for supporting the heart's more tortuous arteries. The Wiktor Rival system is for treating abrupt or threatened vessel closure in patients with failed interventional therapy or suboptimal percutaneous transluminal coronary angioplasty. The device, which was granted a PMA supplement, has low deployment and post-deployment pressures to protect vessel tissue and eliminate the need for high-pressure balloon catheters, which are time consuming to use and add to cost.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.